Data from Amylyx's CENTAUR trial shows promise in slowing ALS progression -

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline in patients with ALS compared with placebo.

We join with the ALS community worldwide in the excitement over this new data and wanted to provide you with links to the Journal report and a news article that explain the findings in more detail.

New England Journal of Medicine – Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

Neurology Live – AMX0035 Slows Functional Decline in ALS in Phase 2/3

Sabrina Paganoni, MD, PhD, assistant professor at Harvard Medical School and physician-scientist at the Healey Center for ALS at Massachusetts General Hospital, served as principal investigator on the CENTAUR trial. She is also the keynote speaker at our 10th Annual Les Turner Symposium on ALS to be held virtually this year on November 9. Dr. Paganoni will be presenting on the HEALEY ALS Platform Trial at the Symposium, but will cover some details of the CENTAUR trial in the Clinical Conversations Panel that follows her keynote address.

As we do with all potential new treatments for ALS, we will continue to monitor the situation and provide you with additional information through email, social media and our website as it becomes available in the coming months.Together toward a cure,

Andrea Pauls Backman, Chief Executive Officer